Overview

Sevoflurane In Acute Myocardial Infarction

Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
Ischemic postconditioning can reduce myocardial injury following myocardial infarction. A potential pharmacological agent is the anesthetic Sevoflurane. The investigators' hypothesis is that sevoflurane during primary percutaneous coronary intervention (PCI) will reduce infarct size.
Phase:
Phase 2
Details
Lead Sponsor:
Lawson Health Research Institute
Treatments:
Sevoflurane